Ipsen has finalized the acquisition of the American company Epizyme specialized in oncology

PARIS (Agefi-Dow Jones)–The pharmaceutical company Ipsen announced on Friday the finalization of the definitive merger agreement under which it acquired Epizyme, an American biopharmaceutical company specializing in oncology. Epizyme now operates as ‘a company of the Ipsen group’. Ipsen had announced this operation at the end of June for an initial amount estimated at 247 million dollars (234 million euros). As part of the transaction, Ipsen acquires Epizyme’s lead drug, Tazverik (tazemetostat), which is already approved by US authorities for the treatment of certain follicular lymphomas. ([email protected]) ed: VAT

Agefi-Dow Jones The financial newswire

Dow Jones Newswires

August 12, 2022 11:58 ET (15:58 GMT)